MX347372B - Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. - Google Patents

Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.

Info

Publication number
MX347372B
MX347372B MX2012013617A MX2012013617A MX347372B MX 347372 B MX347372 B MX 347372B MX 2012013617 A MX2012013617 A MX 2012013617A MX 2012013617 A MX2012013617 A MX 2012013617A MX 347372 B MX347372 B MX 347372B
Authority
MX
Mexico
Prior art keywords
metformin
glucokinase activator
activator
combination
compositions
Prior art date
Application number
MX2012013617A
Other languages
English (en)
Other versions
MX2012013617A (es
Inventor
M M Mjalli Adnan
Carmen Valcarce Lopez Maria
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2012013617A publication Critical patent/MX2012013617A/es
Publication of MX347372B publication Critical patent/MX347372B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención proporciona usos de un activador de glucoquinasa en combinación con metformina. Los usos incluyen el tratamiento de diabetes tipo 2, la disminución de la glucosa en sangre, el mejoramiento de la sensibilidad a la insulina, el mejoramiento de la fosforilación de la glucosa y el mejoramiento de la eficacia terapéutica de metformina. La invención también proporciona composiciones farmacéuticas que comprenden un activador de GK y metformina. La invención también proporciona una sal formada entre metformina y un activador de GK.
MX2012013617A 2010-05-26 2011-05-24 Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. MX347372B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34855410P 2010-05-26 2010-05-26
PCT/US2011/037752 WO2011149945A1 (en) 2010-05-26 2011-05-24 Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator

Publications (2)

Publication Number Publication Date
MX2012013617A MX2012013617A (es) 2013-03-20
MX347372B true MX347372B (es) 2017-04-25

Family

ID=45004334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013617A MX347372B (es) 2010-05-26 2011-05-24 Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.

Country Status (30)

Country Link
US (4) US9359313B2 (es)
EP (1) EP2576524B1 (es)
JP (1) JP5902676B2 (es)
KR (2) KR101860120B1 (es)
CN (1) CN102906077B (es)
AU (1) AU2011258460B2 (es)
BR (1) BR112012029844A2 (es)
CA (1) CA2799591C (es)
CO (1) CO6640324A2 (es)
CY (1) CY1119850T1 (es)
DK (1) DK2576524T3 (es)
EA (1) EA032085B1 (es)
ES (1) ES2655396T3 (es)
HK (1) HK1181044A1 (es)
HR (1) HRP20180113T1 (es)
HU (1) HUE036009T2 (es)
IL (1) IL223137A0 (es)
LT (1) LT2576524T (es)
ME (1) ME03007B (es)
MX (1) MX347372B (es)
NO (1) NO2576524T3 (es)
NZ (1) NZ603614A (es)
PE (1) PE20130275A1 (es)
PL (1) PL2576524T3 (es)
PT (1) PT2576524T (es)
RS (1) RS56761B1 (es)
SG (1) SG185660A1 (es)
SI (1) SI2576524T1 (es)
TW (1) TWI508723B (es)
WO (1) WO2011149945A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101860120B1 (ko) * 2010-05-26 2018-05-23 브이티브이 테라퓨틱스 엘엘씨 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
MX360304B (es) 2012-05-17 2018-10-29 Vtv Therapeutics Llc Composiciones de activador de glucocinasa para el tratamiento de la diabetes.
KR102694699B1 (ko) * 2013-03-04 2024-08-12 브이티브이 테라퓨틱스 엘엘씨 글루코키나제 활성화제를 포함하는 고체 조성물 및 그것의 제조 및 사용 방법
WO2014137797A2 (en) * 2013-03-04 2014-09-12 Transtech Pharma, Llc Stable glucokinase activator compositions
CA3042055A1 (en) * 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
KR102695132B1 (ko) * 2018-05-31 2024-08-14 후아 메디슨 (상하이) 엘티디. 글루코키나제 활성화제 및 비구아니드 혈당 저하 약물을 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
US20230219909A1 (en) * 2020-06-08 2023-07-13 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
KR20230048501A (ko) * 2020-06-08 2023-04-11 브이티브이 테라퓨틱스 엘엘씨 ｛2-[3-사이클로헥실-3-(트랜스-4-프로폭시-사이클로헥실)-우레이도]-티아졸-5-일설파닐｝-아세트산의 결정형 및 그의 용도
CN115073330A (zh) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 二甲双胍肉桂酸盐及制备方法和其组合物与用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT323195B (de) * 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
FR2243684B1 (es) * 1973-09-19 1977-01-28 Semb
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
MXPA05000130A (es) 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
ITRM20030053A1 (it) * 2003-02-10 2004-08-11 Sigma Tau Ind Farmaceuti Associazione di farmaci antidiabetici.
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
WO2005066145A1 (en) * 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
CA2582567A1 (en) * 2004-10-07 2006-04-13 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
MX2008000294A (es) * 2005-07-08 2008-04-04 Novo Nordisk As Activadores de dicicloalquil urea glucocinasa.
WO2007006761A1 (en) * 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
CN101263131B (zh) * 2005-07-14 2013-04-24 特兰斯特克药品公司 脲葡糖激酶活化剂
JP2010515701A (ja) * 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
BRPI0912802A2 (pt) 2008-05-16 2015-10-13 Takeda San Diego Inc ativadores de glicoquinase
WO2011025270A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학조성물 및 그를 포함하는 복합제제
KR101860120B1 (ko) * 2010-05-26 2018-05-23 브이티브이 테라퓨틱스 엘엘씨 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
MX360304B (es) 2012-05-17 2018-10-29 Vtv Therapeutics Llc Composiciones de activador de glucocinasa para el tratamiento de la diabetes.
WO2014137797A2 (en) 2013-03-04 2014-09-12 Transtech Pharma, Llc Stable glucokinase activator compositions
KR102694699B1 (ko) 2013-03-04 2024-08-12 브이티브이 테라퓨틱스 엘엘씨 글루코키나제 활성화제를 포함하는 고체 조성물 및 그것의 제조 및 사용 방법

Also Published As

Publication number Publication date
AU2011258460B2 (en) 2015-02-19
LT2576524T (lt) 2017-12-27
US20110313007A1 (en) 2011-12-22
US9359313B2 (en) 2016-06-07
JP5902676B2 (ja) 2016-04-13
NO2576524T3 (es) 2018-03-24
SG185660A1 (en) 2012-12-28
PL2576524T3 (pl) 2018-03-30
JP2013526608A (ja) 2013-06-24
HK1181044A1 (en) 2013-11-01
EA201201617A1 (ru) 2013-04-30
HUE036009T2 (hu) 2018-06-28
EA032085B1 (ru) 2019-04-30
KR20180028539A (ko) 2018-03-16
TW201201791A (en) 2012-01-16
KR101878252B1 (ko) 2018-07-13
PT2576524T (pt) 2017-11-17
ME03007B (me) 2018-10-20
AU2011258460A1 (en) 2013-01-10
US20160184277A1 (en) 2016-06-30
IL223137A0 (en) 2013-02-03
EP2576524B1 (en) 2017-10-25
US20170354647A1 (en) 2017-12-14
CO6640324A2 (es) 2013-03-22
MX2012013617A (es) 2013-03-20
BR112012029844A2 (pt) 2015-10-13
CN102906077A (zh) 2013-01-30
NZ603614A (en) 2014-10-31
EP2576524A1 (en) 2013-04-10
ES2655396T3 (es) 2018-02-19
PE20130275A1 (es) 2013-03-17
EP2576524A4 (en) 2014-03-05
TWI508723B (zh) 2015-11-21
WO2011149945A1 (en) 2011-12-01
US9855251B2 (en) 2018-01-02
SI2576524T1 (en) 2018-01-31
CA2799591C (en) 2019-06-11
DK2576524T3 (en) 2018-01-22
CY1119850T1 (el) 2018-06-27
CN102906077B (zh) 2015-03-04
RS56761B1 (sr) 2018-04-30
US10363244B2 (en) 2019-07-30
HRP20180113T1 (hr) 2018-02-23
KR101860120B1 (ko) 2018-05-23
US20180344706A1 (en) 2018-12-06
CA2799591A1 (en) 2011-12-01
US10064846B2 (en) 2018-09-04
KR20130109015A (ko) 2013-10-07

Similar Documents

Publication Publication Date Title
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201100621A1 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
EA201170149A1 (ru) Новые аналоги инсулина пролонгированной активности
EA201991014A1 (ru) Лечение диабета
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
MY152172A (en) Therapeutic agent for diabetes
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
MX362503B (es) Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal.
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
MX360304B (es) Composiciones de activador de glucocinasa para el tratamiento de la diabetes.
PH12019502655A1 (en) Acylated insulin compound
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
MX366685B (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
MY154376A (en) A transdermal fluid
PH12020500532A1 (en) Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin
MX2014001271A (es) Tratamiento de diabetes de tipo 2 con fty720.
MX2020002312A (es) Farmaceutica combinada que comprende dapagliflozina l-prolina y metformina.
TN2016000064A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
UA85523C2 (ru) Применение n-стеароилэтаноламина в качестве лекарственного средства для терапии сахарного диабета і и іі типов

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: VTV THERAPEUTICS LLC

HC Change of company name or juridical status

Owner name: VTV THERAPEUTICS LLC

GB Transfer or rights

Owner name: VTV THERAPEUTICS LLC

HC Change of company name or juridical status

Owner name: VTV THERAPEUTICS LLC

FG Grant or registration